Drawing for SEQUOIA BIOTECH CONSULTING

USPTO serial 98377908

SEQUOIA BIOTECH CONSULTING

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
STURMAN, JOSHUA M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SEQUOIA BIOTECH CONSULTING?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sara M. Bauer

Sara M. Bauer WOMBLE BOND DICKINSON (US) LLPINDEPENDENCE WHARF470 ATLANTIC AVE; SUITE 600BOSTON, MA 02210

Goods and services

ClassDescriptionStatusFirst use
035Business advisory, development, and strategic planning services provided to companies in the life sciences industries; providing business program management services to companies in the life sciences industries; providing business consulting services to assist life sciences organizations and affiliates in the fields of business strategy, product development, new technology implementation, mergers and acquisitions, operational and organization effectiveness; business services, namely, formulation of best practices for life science companies; regulatory submission management, namely, assisting others in preparing and filing documents for approval of therapeutics, diagnostics, and medical devices with governmental regulatory bodies; consulting in the field of regulatory compliance and operations, quality compliance and operations, technology, and productivity to life sciences companies with respect to therapeutics, diagnostics and medical devicesABANDONED—
042technical advisory services in the fields of biotechnology, diagnostics, therapeutics, and medical devices; technical consulting services, namely, providing scientific expertise required for technology transfer, method validation, analytical support, chemistry, manufacturing, and controls (CMC), and quality control; technical consulting services, namely, providing engineering expertise required for technology transfer, automation, process engineering, commissioning, qualification, and validation of equipment and facilities, facility management, and equipment maintenance and support; consulting services for biotechnology, diagnostic, therapeutic and medica device companies in designing, planning, and managing of laboratory moves, new facility builds, and commissioning, qualifying, and validating facilities and equipment; providing consulting services to assist life sciences organizations and affiliates in the fields of product development and new technology implementation; consulting in the field of quality compliance and operations and technology to life sciences companies with respect to therapeutics, diagnostics and medical devices; quality management consulting in the fields of biotechnology, diagnostics, therapeutics, and medical devicesABANDONED—
045Regulatory compliance and risk management consulting in the fields of biotechnology, diagnostics, therapeutics, and medical devices; consulting in the field of regulatory compliance to life sciences companies with respect to therapeutics, diagnostics and medical devicesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 9, 2025ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Jan 25, 2025MAB5ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION—
Jan 25, 2025ABN5ABANDONMENT - AFTER PUBLICATION—
Jan 24, 2025EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Jan 7, 2025ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 10, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 10, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 4, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 13, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 11, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 11, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 11, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 26, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 22, 2024DOCKASSIGNED TO EXAMINER—
Feb 9, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 30, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance